Celyad Oncology S.A. (CYAD) Stock Analysis

What Celyad Oncology S.A. does

Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing novel chimeric antigen receptor T (CAR-T) cell therapies aimed at combating various cancers. The company boasts several promising therapeutic candidates in clinical trials. CYAD-101, an allogeneic CAR-T cell therapy, is currently undergoing Phase 1b trials for patients with metastatic colorectal cancer. Another allogeneic, shRNA-based CAR-T candidate, CYAD-211, is in Phase 1 for individuals suffering from relapsed/refractory multiple myeloma. Additionally, CYAD-02, an autologous CAR-T therapy, is being evaluated in Phase 1 for relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, Celyad is developing CYAD-203. This is a non-gene edited allogeneic CAR-T candidate engineered to co-express the cytokine interleukin-18 (IL-18) alongside natural killer group 2D ligands (NKG2D), targeting solid tumors. Celyad has also forged strategic alliances. It holds a licensing agreement with Novartis International AG concerning US patents for allogeneic CAR-T cell technology. Furthermore, the company has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to establish a second non-gene-edited allogeneic platform. Founded in 2004, the company was initially named Celyad SA, but rebranded to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.

Key metrics

ETFs linked to CYAD

Broad-market and Healthcare sector ETFs an investor holding Celyad Oncology S.A. is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CYAD fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Celyad Oncology S.A.?

Celyad Oncology S.A. trades under the ticker CYAD on NASDAQ.

Which exchange is CYAD listed on?

CYAD is listed on NASDAQ.

What sector does Celyad Oncology S.A. operate in?

Celyad Oncology S.A. is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CYAD in a portfolio?

PortView shows CYAD's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.